
ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially "best-in-class" treatments. The company’s shares have not had a great year, returning -4% in 2024. However, analysts on Wall Street are bullish.
The average of five price targets released since the beginning of Sept. is $19.60 per share. The company’s stock price would have to rise 122% to reach that level. So, what is making these analysts optimistic about the stock? I’ll look to answer that question and provide my take on ORIC Pharmaceuticals.